Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma

Sex and gender disparities have been reported for different types of non-reproductive cancers. Males are two times more likely to develop kidney cancer than females and have a higher death rate. These differences can be explained by looking at genetics and genomics, as well as other risk factors such as hypertension and obesity, lifestyle, and female sex hormones. Examination of the hormonal signaling pathways bring further insights into sex-related differences. Sex and gender-based disparities can be observed at the diagnostic, histological and treatment levels, leading to significant outcome difference. This review summarizes the current knowledge about sex and gender-related differences in the clinical presentation of patients with kidney cancer and the possible biological mechanisms that could explain these observations. Underlying sex-based differences may contribute to the development of sex-specific prognostic and diagnostic tools and the improvement of personalized therapies.

show abstract

“…In a complementary study, Decat Bergerot et al, reported that younger, female patients had an increased fear of cancer recurrence [167].…”

Section: Discussionmentioning

confidence: 98%

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Peired

Campi

Angelotti

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…With the rise of novel targeted‐ and immuno‐therapy regimens, urologists and oncologist also need to learn how to capture, treat and monitor new side‐effects associated with these treatments (Grimm et al, 2010). In addition, especially female and young RCC cancer survivors experience clinically relevant fear of cancer recurrence (Bergerot et al, 2020). These psychological comorbidities impose a significant impact on the health‐related quality of life after treatment.…”

Section: Discussionmentioning

confidence: 99%

Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma

Michaeli

Boch

et al. 2022

European J Cancer Care

View full text Add to dashboard Cite

Objective The objective of this study is to assess the risk‐stratified 10‐year socio‐economic burden of renal cell carcinoma (RCC) follow‐up costs after initial treatment in Germany from 2000 to 2020. Methods A micro‐costing method considering direct and indirect medical expenditure associated with follow‐up procedures was employed to calculate survivorship costs per patient. The frequencies of physician–patient visits, examinations and diagnostic tests were extracted from guidelines, whilst expenses were sourced from literature and official scales of tariffs. Societal costs were calculated based on three perspectives: patients, providers and insurers. Results Mean societal 10‐year follow‐up costs per patient amounted to EUR 3,377 (95%CI: 2,969–3,791) for low‐risk, EUR 3,367 (95%CI: 3,003–3,692) for medium‐risk and EUR 4,299 (95%CI: 3,807–4,755) for high‐risk RCC in 2020. Spending increased by +32% from 2000 to 2020 for low‐risk RCC, whilst medium‐and high‐risk RCC expenditure was cut by −39% and −22%, respectively. Patients shouldered 27%, providers 43% and insurers 35% of costs in 2020. Resources were consumed by medical imaging (52%), physician‐patient consultations (31%), travel expenses (17%) and blood tests (1%). Conclusion Results highlight the economic burden cancer survivorship poses for society. Cancer survivors require individualised, evidence‐based and insurance‐covered follow‐up schedules to permit the early detection of side‐effects, metastasis and secondary malignancies.

show abstract

“…Approximately half of cancer survivors experience clinically significant FCR [ 3 , 4 ], which is associated with psychological distress, poorer quality of life (QoL) and greater healthcare use [ 1 , 5 ]. FCR is more prevalent amongst survivors who are female [ 1 , 4 , 6 ] and younger [ 1 , 4 , 6 ] and experience physical symptoms [ 1 , 7 – 9 ]. If untreated, FCR can persist for many years, highlighting the need for intervention [ 1 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Feasibility and preliminary efficacy of iConquerFear: a self-guided digital intervention for fear of cancer recurrence

et al. 2022

Self Cite

View full text Add to dashboard Cite

Purpose Approximately 50% of cancer survivors experience moderate-severe fear of cancer recurrence (FCR). Self-guided digital interventions have potential to address the high level of FCR-related unmet needs at scale, but existing digital interventions have demonstrated variable engagement and efficacy. This study aimed to evaluate the feasibility and preliminary efficacy of iConquerFear, a five-module self-guided digital FCR intervention. Methods Eligible curatively treated breast cancer survivors were recruited. Participants reporting clinically significant FCR (≥ 13 on the Fear of Cancer Recurrence Inventory-Short Form; FCRI-SF) were given access to iConquerFear. Feasibility was indicated by > 50% of eligible participants enrolling in iConquerFear and recording moderate (≥ 120 min) or greater usage. Preliminary efficacy was evaluated via changes in self-reported FCR severity, anxiety, depression, intrusions and metacognitions from baseline to immediately and 3 months post-intervention. Results Fifty-four (83%) of 65 eligible participants enrolled in iConquerFear; six subsequently withdrew. Thirty-nine (83%) participants recorded moderate (n = 24; 120–599 min) or high (n = 15; ≥ 600 min) usage. Engagement levels increased with participant age (p = 0.043), but were lower in participants with higher baseline FCR (p = 0.028). Qualitative feedback indicated engagement was sometimes limited by difficulties with navigation and relating to featured survivors. Participants reported significantly improved FCR (mean reduction (95%CI): baseline to post-intervention − 3.44 (− 5.18, − 1.71), baseline to 3-month follow-up − 4.52 (− 6.25, − 2.78), p = < 0.001). Conclusion iConquerFear is a feasible and potentially efficacious intervention for reducing FCR in breast cancer survivors. Easier navigation and more relatable examples may enhance engagement. Implications for Cancer Survivors iConquerFear may help address moderate but burdensome FCR levels in cancer survivors.

show abstract

Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma

Cited by 23 publications

References 32 publications

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma

Feasibility and preliminary efficacy of iConquerFear: a self-guided digital intervention for fear of cancer recurrence

Contact Info

Product

Resources

About